<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03493269</url>
  </required_header>
  <id_info>
    <org_study_id>18385</org_study_id>
    <secondary_id>2017-001817-10</secondary_id>
    <nct_id>NCT03493269</nct_id>
  </id_info>
  <brief_title>A Multiple Dose Study of BAY1834845 in Healthy Male Subjects and in Patients With Psoriasis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics and Exploratory Pharmacodynamics of Multiple Oral Doses of BAY1834845 in Healthy Male Subjects and in Female and Male Patients With Psoriasis Over an Extended Treatment Duration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess safety and tolerability of multiple oral doses of BAY1834845 in healthy male&#xD;
      subjects (Part 1) and in patients with psoriasis (Part 2).&#xD;
&#xD;
      To assess the pharmacokinetic (PK) properties of total BAY1834845 in plasma after oral&#xD;
      multiple doses of BAY1834845 in healthy male subjects (Part 1) and patients with psoriasis&#xD;
      (Part 2).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 16, 2018</start_date>
  <completion_date type="Actual">February 5, 2021</completion_date>
  <primary_completion_date type="Actual">September 16, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double blind</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Approximately 47 days</time_frame>
    <description>Part 1 in healthy male subject</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Approximately 47 days</time_frame>
    <description>Part 1 in healthy male subject</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Approximately 84 days</time_frame>
    <description>Part 2: Patients with psoriasis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Approximately 84 days</time_frame>
    <description>Part 2: Patients with psoriasis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-24)md of BAY1834845</measure>
    <time_frame>Part 1 - Period 1 (dose group 1-4): Day 1 to 2 Part 1 - Period 2 (dose group 5): Day 1 to 2</time_frame>
    <description>Part 1 AUC(0-24)md: AUC from zero to 24 hours after multiple dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-12)md of BAY1834845</measure>
    <time_frame>Part 1 - Period 1 (dose group 1-4): Day 1, Part 1 - Period 2 (dose group 5): Day 1</time_frame>
    <description>Part 1 AUC(0-12)md:AUC from zero to 12 hours after multiple dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,md of BAY1834845</measure>
    <time_frame>Part 1 - Period 1 (dose group 1-4): Day 1, Part 1 - Period 2 (dose group 5): Day 1</time_frame>
    <description>Part 1 Cmax,md:Cmax(Maximum observed drug concentration, directly taken from analytical data) after multiple dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cav,md of BAY1834845</measure>
    <time_frame>Part 1 - Period 1 (dose group 1-4): Day 1 to 2 Part 1 - Period 2 (dose group 5): Day 1 to 2</time_frame>
    <description>Part 1 Cav:Average concentration within a dosing interval after multiple dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-24)md of BAY1834845</measure>
    <time_frame>Part 2: one day between day 35 and 42</time_frame>
    <description>Part 2: AUC(0-24)md: AUC from zero to 24 hours after multiple dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-12)md of BAY1834845</measure>
    <time_frame>Part 2: one day between day 35 and 42</time_frame>
    <description>Part 2: AUC(0-12)md: AUC from zero to 12 hours after multiple dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,md of BAY1834845</measure>
    <time_frame>Part 2: one day between day 35 and 42</time_frame>
    <description>Part 2: Cmax,md:Cmax (Maximum observed drug concentration, directly taken from analytical data) after multiple dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cav, md of BAY1834845</measure>
    <time_frame>Part 2: one day between day 35 and 42</time_frame>
    <description>Part 2: Cav: Average concentration within a dosing interval after multiple dosing</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>BAY1834845</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1 in healthy male subjects:&#xD;
Dose Groups 1-4 : orally administered multiple ascending doses. The treatment will last 10 consecutive days (treatment period1) and 1 day (treatment period 2) Dose Group 5: The treatment will last 1 day (treatment period 1) and 10 consecutive days (treatment period 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part 1: Matching placebo in healthy male subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chosen dose of BAY1834845</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2: This dose level will be adminstered in female and male patients with psoriasis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part 2: The placebo will be adminstered in female and male patients with psoriasis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1834845</intervention_name>
    <description>Orally administered.</description>
    <arm_group_label>BAY1834845</arm_group_label>
    <arm_group_label>Chosen dose of BAY1834845</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Orally administered.</description>
    <arm_group_label>Matching Placebo</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Part 1: Orally administered 1mg as a single dose.</description>
    <arm_group_label>BAY1834845</arm_group_label>
    <arm_group_label>Matching Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Part 1 (healthy male subjects)&#xD;
&#xD;
          -  Healthy male subjects, 18 to 50 years of age (inclusive), and in good health as&#xD;
             determined by medical history, physical examination, vital signs, electrocardiogram&#xD;
             (ECG), and laboratory tests at screening&#xD;
&#xD;
          -  Body mass index (BMI) above or equal to 18.5 and lower or equal to 30 kg/m2 (BMI =&#xD;
             body weight (kg) / [height (m)]2 and a body weight above or equal 50 kg Part 2&#xD;
             (patients with psoriasis)&#xD;
&#xD;
          -  Male patients, 18 to 70 years of age (inclusive) or female patients of non-child&#xD;
             bearing potential, 30 to 70 years of age (inclusive)&#xD;
&#xD;
          -  Body mass index above or equal to 18.5 and lower or equal to 35 kg/m*2 and a body&#xD;
             weight above 50 kg&#xD;
&#xD;
          -  A documented diagnosis of psoriasis, with a history of at least 6 months prior to&#xD;
             study drug administration. Moderate to severe plaque psoriasis at screening, defined&#xD;
             by: a) an involved body surface area (BSA) above or equal to 10% of BSA, b) a&#xD;
             Psoriasis Area and Severity Index (PASI) score of above or equal, 12 c) a Physician's&#xD;
             Global Assessment (PGA) score of above or equal 2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of hypersensitivity to any of the components of the study drug&#xD;
&#xD;
          -  Any clinically relevant abnormal findings in safety laboratory parameters and ECG&#xD;
&#xD;
          -  History of tuberculosis (TB) or active or latent tuberculosis&#xD;
&#xD;
          -  Receipt of live or attenuated vaccine 90 days prior to the first dosing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité Research Organisation GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PAREXEL GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 4, 2018</study_first_submitted>
  <study_first_submitted_qc>April 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2018</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

